

Lenz Sales and Distributing Inc 4825 Waverly Rd NEW BERLIN IL 62670 US Performance Materials and Technologies 115 Tabor Road Morris Plains, NJ 07950 ATTN: SDS Coordinator

September 21, 2024

Dear Sir or Madam:

As a Responsible Care® company, Honeywell is focused on maintaining a high quality Product Stewardship program. To that end, our customers are sent Safety Data Sheets (SDSs) whenever:

- you purchase a product for the first time in a given calendar year,
- a SDS is significantly revised and/or updated
- the product contains a chemical(s) that is listed under Section 313 of the Emergency Planning and Community Right-To-Know Act of 1986.

10322628 Genetron® 245fa

Customer PO Number

Customer Material Number

ICETHRM919

Enclosed are the current SDSs for Honeywell International Inc. products purchased by your company. It is imperative that you read and understand these SDSs, and that copies be permanently maintained on file at your facility. In addition, if you redistribute the products, these SDSs must also be provided to downstream employers receiving the products. If you or your department is not responsible for these files, please forward this information accordingly.

Should you have questions, or require any additional information about these products, please refer to Section 1 of the SDS for contact information.

Sincerely,

Honeywell Product Stewardship Global Operations

This letter was generated by electronic data processing and therefore has no signature.

Enclosure(s)

Honeywell

Genetron® 245fa

| 10322628 | | | |
|------------------------------|-----------|--------------------------------------|-----------------------|
| Version 2.13 | Re | evision Date 09/22/2023 | Print Date 09/20/2024 |
| SECTION 1. IDENTIFICATION | | | |
| SECTION 1. IDENTIFICATION | | | |
| Product name | : Gen | etron® 245fa | |
| | | | |
| Number | : 0000 | 00009878 | |
| Product Use Description | : Refr | igerant, Heat transfer fluid | |
| | | .g | |
| Manufacturer or supplier's | : Hone | eywell International Inc. | |
| details | 115 | Tabor Road | |
| For more information call | | is Plains, NJ 07950-2546 522-8001 | |
| | | 73-455-6300(Monday-Friday, 9 | :00am-5:00pm) |
| In case of emergency call | : Med | lical: 1-800-498-5701 or +1-303 | 3-389-1414 |
| | | nsportation (CHEMTREC): 1-8 | 00-424-9300 or |
| | +1-7 : | 03-527-3887 | |
| | : (24 ł | nours/day, 7 days/week) | |
| | | | |
| SECTION 2. HAZARDS IDENTIF | | | |
| Emergency Overview | | | |
| | | | |
| Form | : Liqu | uefied gas | |
| Color | : colo | ourless | |
| Odor | : wea | ak | |
| | | | |
| | | | |
| Classification of the substa | nce or n | nixture | |
| | | ases under pressure, Liquefied g | nas |
| or mixture | | nple Asphyxiant | yas |
| | | | |
| GHS Label elements, includ | ling proc | cautionary statements | |
| | my prec | autionaly statements | |
| | | | |
| | | Page 1 / 15 | |
| | | | |
| | | | |
| | | | |

| | - | Honeywell |
|---|--|--|
| netron® 245fa | | |
| 322628 sion 2.13 | Revision Date 09/22/2023 | Print Date 09/20/20 |
| Symbol(s) | : | |
| Signal word | : Warning | |
| Hazard statements | : Contains gas under pressure; May displace oxygen and caus | |
| Precautionary statements | : Prevention: Use personal protective equip | ment as required. |
| | Storage: Protect from sunlight. Store in | a well-ventilated place. |
| Hazards not otherwise classified | : May cause eye and skin irritati May cause cardiac arrhythmia | |
| • • • • • | | |
| anticipated carcinogen by NT | present at levels greater than or equar P, IARC, or OSHA. CORMATION ON INGREDIENTS | al to 0.1% is identified as a know |
| No component of this product anticipated carcinogen by NT | P, IARC, or OSHA. | al to 0.1% is identified as a know |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF | P, IARC, or OSHA. | al to 0.1% is identified as a know |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF | P, IARC, or OSHA. | |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature | P, IARC, or OSHA. ORMATION ON INGREDIENTS CHF2CH2CF3 Substance name CAS-N | o. Concentration |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature Chemical | P, IARC, or OSHA. CORMATION ON INGREDIENTS : CHF2CH2CF3 : Substance name CAS-N e 460-73 | o. Concentration |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature 1,1,1,3,3-Pentafluoropropane | P, IARC, or OSHA. CORMATION ON INGREDIENTS : CHF2CH2CF3 : Substance name CAS-N e 460-73 | o. Concentration -1 100.00 % hing, give artificial respiration. If |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature (Chemical nature 1,1,1,3,3-Pentafluoropropane) CTION 4. FIRST AID MEASU | P, IARC, or OSHA. | o. Concentration -1 100.00 % hing, give artificial respiration. If |
| No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature (Chemical nature 1,1,1,3,3-Pentafluoropropane) CTION 4. FIRST AID MEASU | P, IARC, or OSHA. FORMATION ON INGREDIENTS : CHF2CH2CF3 : Substance name CAS-N e 460-73 RES : Remove to fresh air. If not breatt breathing is difficult, give oxyger | o. Concentration -1 100.00 % hing, give artificial respiration. |

Honeywell

Genetron® 245fa

| 10322628 |
|----------|
|----------|

| 10322628 | | | |
|---|----|---|---|
| Version 2.13 | | Revision Date 09/22/2023 | Print Date 09/20/2024 |
| | | provided a qualified operator is preser | nt. Call a physician. |
| Skin contact | : | After contact with skin, wash immedia symptoms persist, call a physician. Ta clothing immediately. Wash contamina re-use. | ake off all contaminated |
| Eye contact | : | Rinse immediately with plenty of wate for at least 15 minutes. Call a physicia persists. | |
| Ingestion | : | If victim is fully conscious, give a cupfe vomiting without medical advice. Neve to an unconscious person. Call a phys | er give anything by mouth |
| Notes to physician | | | |
| Indication of immediate medical attention and special treatment needed, if necessary | : | Treat symptomatically. | |
| SECTION 5. FIREFIGHTING MEA | sı | IRES | |
| Suitable extinguishing media | | The product is not flammable. Use extinguishing measures that are circumstances and the surrounding e Water spray Carbon dioxide (CO2) Dry chemical Foam | |
| Specific hazards during firefighting | | This product is not flammable at amb atmospheric pressure. However, this material can ignite whe pressure and exposed to strong igniti Container may rupture on heating. Cool closed containers exposed to fir Do not allow run-off from fire fighting courses. Vapours are heavier than air and can reducing oxygen available for breathin Exposure to decomposition products health. | en mixed with air under ion sources. re with water spray. to enter drains or water n cause suffocation by ing. |
| | | Page 3 / 15 | |
| | | | |

Honeywell

Genetron® 245fa

| 322628 sion 2.13 | Revision Date 09/22/2023 | Print Data 00/20/2 |
|---|---|--|
| 5011 2.13 | | Print Date 09/20/2 |
| | Fire may cause evolution o Hydrogen fluoride Gaseous hydrogen chloride Carbon oxides Halogenated compounds Carbonyl halides | |
| Special protective equipment for firefighters | | explosion do not breathe fumes. Ning apparatus and protective suit. Kin areas. |
| TION 6. ACCIDENTAL RELI | ASE MEASURES | |
| Personal precautions, protective equipment and emergency procedures | must be kept away. Remove all sources of igniti Ventilate the area. Vapours are heavier than ai reducing oxygen available for Avoid accumulation of vapo | l upwind of spill/leak. quipment. Unprotected persons on. r and can cause suffocation by or breathing. urs in low areas. uld not return until air has been |
| Environmental precautions | Prevent further leakage or s | ter or sanitary sewer system. pillage if safe to do so. ide area (e.g. by containment or oil |
| Methods and materials for containment and cleaning up | | nd, earth, diatomaceous earth, ntainer for disposal according to |
| TION 7. HANDLING AND ST | ORAGE | |
| Handling | | |
| Precautions for safe | : Handle with care. | |
| | Page 4 / 15 | |

Honeywell

Genetron® 245fa

| 10322628 | | | |
|--|----|---|---|
| Version 2.13 | | Revision Date 09/22/2023 | Print Date 09/20/2024 |
| handling | | Do not use in areas without adequat Do not breathe vapours or spray mis Avoid contact with skin, eyes and cle Follow all standard safety precaution compressed gas cylinders. Use authorized cylinders only. Protect cylinders from physical dam Do not puncture or drop cylinders, ex excessive heat. Do not pierce or burn, even after use flame or any incandescent material. Do not remove screw cap until imme Always replace cap after use. | st. othing. ns for handling and use of age. kpose them to open flame or e. Do not spray on a naked |
| Advice on protection against fire and explosion | : | Can form a combustible mixture with atmospheric pressure. Keep product and empty container a of ignition. | |
| Storage | | | |
| Conditions for safe storage, including any incompatibilities | : | Pressurized container. Protect from to temperatures exceeding 55 °C. Keep containers tightly closed in a d place. Storage rooms must be properly ver Ensure adequate ventilation, especi Protect cylinders from physical dama Store away from incompatible subst | try, cool and well-ventilated ntilated. ally in confined areas. age. |
| SECTION 8. EXPOSURE CONTROL | OL | S/PERSONAL PROTECTION | |
| Protective measures | : | Ensure that eyewash stations and so the workstation location. Do not breathe vapours or spray mis Avoid contact with skin, eyes and cle | st. |
| Engineering measures | : | Use with local exhaust ventilation. Perform filling operations only at sta ventilation facilities. | tions with exhaust |
| Eye protection | : | Wear as appropriate: | |
| | | Page 5 / 15 | |
| | | | |

Honeywell

Genetron® 245fa

10322628

| sion 2.13 | Revision Date 09/22/2023 | Print Date 09/20/2 |
|--------------------------|--|--|
| | Safety glasses with side-shields Safety goggles | |
| Hand protection | : Impervious gloves Gloves must be inspected prior to Replace when worn. | o use. |
| Skin and body protection | : Wear as appropriate: Solvent-resistant gloves Solvent-resistant apron and boots If splashes are likely to occur, we Protective suit | |
| Respiratory protection | In case of insufficient ventilation vequipment. Wear a positive-pressure supplie For rescue and maintenance wor self-contained breathing apparate Use NIOSH approved respiratory | d-air respirator. k in storage tanks use us. |
| Hygiene measures | Handle in accordance with good in practice. Avoid contact with skin, eyes and Do not breathe vapours or spray Ensure adequate ventilation, esp Remove and wash contaminated Contaminated work clothing shou workplace. Keep working clothes separately. Wash hands before breaks and in product. | d clothing. mist. ecially in confined areas. clothing before re-use. uld not be allowed out of the |

| Components | CAS-No. | Value | Control | Upda | Basis |
|----------------------------------|----------|--------------------------------------|--------------------------|------|---|
| | | | parameters | te | |
| 1,1,1,3,3-Pentaflu oropropane | 460-73-1 | TWA : Time weighted average | 1,644 mg/m3 (300 ppm) | 2020 | WEEL:US. OARS. WEELs Workplace Environmental Exposure Level Guide, as amended |

Page 6 / 15

Honeywell

Genetron® 245fa

10322628 Version 2.13 Print Date 09/20/2024 Revision Date 09/22/2023 **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES** Physical state : Liquefied gas Color : colourless Odor : weak pН : Note: neutral Melting point/range : -103 °C Boiling point/boiling range : 15.3 °C Flash point : Note: Not applicable Evaporation rate : <1 Method: Compared to Ether (anhydrous). : > 1 Method: Compared to CCl4.

| Lower flammability limit | : Note: None |
|--------------------------|---|
| Upper flammability limit | : Note: None |
| Vapor pressure | : 1,227 hPa at 20 °C(68 °F) 3,882 hPa |

Vapor density : 4.6 Note: (Air = 1.0)

Density

Page 7 / 15

at 54.4 °C(129.9 °F)

: 1.32 g/cm3 at 20 °C

Honeywell

Genetron® 245fa

| sion 2.13 | Revision Date 09/22/2023 | Print Date 09/20/20 |
|---|--|--|
| Water solubility | : 7.18 g/l | |
| Solubility in other solvents | : Medium: Methanol Note: partly soluble Medium: Diethylether | |
| | Note: partly soluble | |
| Partition coefficient: n-octanol/water | : log Pow: 1.35 at 21.5 °C Note: The product is more soluble | in octanol. |
| Ignition temperature | : 412 °C | |
| Decomposition temperature | : >250 °C | |
| Molecular weight | : 134.03 g/mol | |
| CTION 10. STABILITY AND R | EACTIVITY | |
| CTION 10. STABILITY AND R Reactivity | EACTIVITY : Not classified as a reactivity hazar | d. |
| | | |
| Reactivity | : Not classified as a reactivity hazar | ge conditions. n sunlight and do not expose ith air at pressures above |
| Reactivity Chemical stability | Not classified as a reactivity hazard Stable under recommended storag Pressurized container. Protect from to temperatures exceeding 55 °C. Can form a combustible mixture w atmospheric pressure. | ge conditions. n sunlight and do not expose ith air at pressures above |
| Reactivity Chemical stability Conditions to avoid | Not classified as a reactivity hazard Stable under recommended storag Pressurized container. Protect from to temperatures exceeding 55 °C. Can form a combustible mixture w atmospheric pressure. Do not mix with oxygen or air abov Strong oxidizing agents Finely divided magnesium | ge conditions. n sunlight and do not expose ith air at pressures above |

| Revision Date 09/22/2023 Print Date 09/20/202 |
|--|
| |
| |
| |
| Carbonyl halides Gaseous hydrogen chloride (HCI). |
| FORMATION |
| : LC50: > 200000 ppm Exposure time: 4 h Species: Rat Note: No deaths Evidence of transient anesthetic effect. |
| : LC50: > 100000 ppm Exposure time: 4 h Species: Mouse Note: No deaths Evidence of transient underactivity during exposure. |
| : LD50: > 2,000 mg/kg Species: Rabbit |
| Cardiac sensitization Species: dogs Note: No effects noted at 35,000 ppm, the threshold for induction of cardiac arrhythmias in the presence of injected adrenalin was 44,000 ppm. |
| : Species: Rat NOEL: 50000 ppm Note: Embryotoxicity Not a teratogen |
| : Species: rat (pups) NOEL: 50000 ppm |
| : Species: rat (dams) NOEL: 2000 ppm Note: due to decrease in body weight gains at 10,000 ppm and 50,000 ppm |
| Page 9 / 15 |
| |

Honeywell

Genetron® 245fa

| Version 2.13 Revision Date 09/22/2023 Print Date 09/20/20 : Species: Rat Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm. : Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study. : Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm : Species: Rat Note: 29-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm : Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm : Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm. This was not noted at the 500 or 2,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study | Species: Rat Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm. Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study. Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm Species: Rat Note: 0-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-2451 is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm. Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v. Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative Species: Mouse Cell type: Bone marrow | 0322628 | | |
|---|---|-----------------------|---|--|
| Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm. Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study. : Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm : Species: Rat Note: 30-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm : Species: Rat Note: 0-verall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver . Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. | Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm. Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study. Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm Species: Rat Note: 00-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm Species: Rat Note: 0-day Inhalation Study Dose levels: urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period Which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm. Genotoxicity in vitro Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v. < | ersion 2.13 | Revision Date 09/22/2023 | Print Date 09/20/2024 |
| Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.: Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm: Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.: Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vivo: Species: Mouse Cell type: Bone marrow | Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.:Species: Rat Note: 24 day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm:Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm.:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative:Species: Mouse Cell type: Bone marrow Application Route: Inhalation | | Method: 2 Generation Inhalation To Note: Exposures 6hrs/day, 7 days/v 10,000 and 50,000 ppm. | |
| Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm:Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 amd 50,000 ppm. This was not noted at the fool or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vitro:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vitro:Species: Mouse Cell type: Bone marrow | Note:28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels:0,500, 2000, 10,000 and 50,000 ppm:Species: Rat Note:90-day Inhalation Study Dose levels:0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Note:Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycaritis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vitro:Species: Mouse Cell type: Bone marrow Application Route: Inhalation | | Note: Toxicity seen in dams at 10,0 pups at 50,000 ppm. Increased mo | |
| Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vivo:Species: Mouse Cell type: Bone marrow | Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vivo: Species: Mouse Cell type: Bone marrow Application Route: Inhalation | | Note: 28-day Inhalation Study NOA effect level) - 50,000 ppm NOEL - 5 | |
| increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vivo:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vivo:Species: Mouse Cell type: Bone marrow | Genotoxicity in vivo: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active time set with S9 up to 70% v/v.Genotoxicity in vivo: Species: Mouse Cell type: Bone marrow Application Route: Inhalation | | Note: 90-day Inhalation Study Dose 10,000 and 50,000 ppm NOAEL (N | |
| Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v. : Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative Genotoxicity in vivo : Species: Mouse Cell type: Bone marrow | Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v. : Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative Genotoxicity in vivo : Species: Mouse Cell type: Bone marrow Application Route: Inhalation | | increases in urinary fluoride levels, consumption. Increases were noted parameters, BUN levels and serum (GOT, GPT). These increases did r however, they indicate that HFC-24 liver. Significant recovery was note following a 2-week, non-exposure p 28-day exposure period. No histopa noted in the 28-day study. The 90-c in incidence and severity (trace to r (inflammation of the heart muscle) a This was not noted at the 500 or 2,0 | urine volumes and water d in hematological liver enzyme activities not follow a dose response; d in these parameters beriod which followed the athological effects were day study noted an increase noderate) of mycarditis at 10,000 and 50,000 ppm. 00 ppm dose levels nor was |
| Metabolic activation: with and without metabolic activation Result: negative Genotoxicity in vivo : Species: Mouse Cell type: Bone marrow : | Genotoxicity in vivo : Species: Mouse Cell type: Bone marrow Application Route: Inhalation | Genotoxicity in vitro | Result: Weak positive activation with | thout S9 at 30% v/v; not |
| Cell type: Bone marrow | Cell type: Bone marrow Application Route: Inhalation | | Metabolic activation: with and witho | out metabolic activation |
| | Page 10 / 15 | Genotoxicity in vivo | Cell type: Bone marrow Application Route: Inhalation | |
| Page 10 / 15 | | | Page 10 / 15 | |

| SAFETY DATA SHEET | Honeywell |
|---|---|
| enetron® 245fa | |
| 0322628 | |
| Version 2.13 | Revision Date 09/22/2023 Print Date 09/20/202 |
| | Method: Mutagenicity (micronucleus test) Result: negative |
| ECTION 12. ECOLOGICAL INFOR | RMATION |
| Ecotoxicity effects | |
| Toxicity to fish | EC50: > 81.8 mg/l Exposure time: 96 h Species: Oncorhynchus mykiss (rainbow trout) |
| | NOEC: > 10 mg/l Exposure time: 96 h Species: Oncorhynchus mykiss (rainbow trout) |
| Toxicity to daphnia and other aquatic invertebrates | : EC50: > 97.9 mg/l Exposure time: 48 h Species: Daphnia magna (Water flea) |
| | : NOEC: > 97.9 mg/l Exposure time: 48 h Species: Daphnia magna (Water flea) |
| Toxicity to algae | : Growth inhibition EC50: > 118 mg/l Species: Algae Method: OECD Test Guideline 201 |
| Elimination information (pers | istence and degradability) |
| Bioaccumulation | : Note: No data available |
| Mobility | : Note: No data available |
| Biodegradability | : Note: No data available |
| | Page 11 / 15 |

| information Agency Cle This productor to global w with provis recovered. Refer to securace Disposal methods Observe all regulations Note Observe all regulations Note Where post SECTION 14. TRANSPORT INFORMATION DOT UN/ID No. : Proper shipping name Class Packing group Hazard Labels IATA UN/ID No. : Class Packing group Hazard Labels Class Hazard Labels Hazard Labels | |
|---|---|
| ersion 2.13 Revision I Further information on ecology Additional ecological information This produte Agency Clean this produte to global weith provis recovered. Refer to sequence performed and the provise recovered. Refer to sequence performed and the provise recovered and the provise recover and the provise | |
| Tersion 2.13 Revision I Further information on ecology Additional ecological information This produte Agency Clean this produte to global weith provis recovered. Refer to sequence ptal to global weith provis recovered. Refer to sequence ptal to global weith provise recovered. Refer to global weith prove ptal to global weith prove ptal to global weit | Nata 00/22/2022 |
| Additional ecological information This produce Agency Cle This produce to global w with provis recovered. Refer to see unacceptal EECTION 13. DISPOSAL CONSIDERATIONS Disposal methods Observe al regulations Note Where pose EECTION 14. TRANSPORT INFORMATION DOT UN/ID No. Proper shipping name Class Packing group Hazard Labels IATA UN/ID No. Class Packing group Hazard Labels Class Packing instruction (cargo :: aircraft) Packing instruction (cargo :: Attal (passenger aircraft) | Date 09/22/2023 Print Date 09/20/2024 |
| information Agency Clear This produto global wwith provis recovered. Refer to set unacceptal ECTION 13. DISPOSAL CONSIDERATIONS Disposal methods : Observe al regulations Note : Where post ECTION 14. TRANSPORT INFORMATION DOT UN/ID No. Proper shipping name : Class Packing group Hazard Labels : Class : Packing instruction (cargo instruction (cargo instruction (cargo instruction (cargo instruction (cargo instruction (cargo instruction (passenger aircraft)) | |
| Disposal methods : Observe all regulations Note : Where possion ECTION 14. TRANSPORT INFORMATION : DOT UN/ID No. : Poper shipping name : Class Packing group Hazard Labels : Class : Packing instruction (cargo : Packing instruction (cargo : Packing instruction (cargo : Packing instruction : | et is subject to U.S. Environmental Protection can Air Act Regulations at 40 CFR Part 82. et contains greenhouse gases which may contribute arming. Do NOT vent to the atmosphere. To comply ons of the U.S. Clean Air Act, any residual must be ctions 610 and 612 for list of acceptable and ole uses for this product. |
| Note Where possible ECTION 14. TRANSPORT INFORMATION Image: Class DOT UN/ID No. Image: Class Proper shipping name Image: Class Packing group Hazard Labels IATA UN/ID No. Image: Class IATA Unit Unit Unit Unit Unit Unit Unit Unit | Federal, State, and Local Environmental |
| DOTUN/ID No. Proper shipping name:Class Packing group Hazard Labels:IATAUN/ID No. Description of the goods:Class Hazard Labels:Class Description of the goods:Class Packing instruction (cargo aircraft) Packing instruction (passenger aircraft): | sible recycling is preferred to disposal or incineration. |
| Description of the goods:Class:Hazard Labels:Packing instruction (cargo:aircraft)Packing instructionPassenger aircraft) | UN 3163 LIQUEFIED GAS, N.O.S. (1,1,1,3,3-Pentafluoropropane) 2.2 2.2 |
| IMDG UN/ID No. : | UN 3163 LIQUEFIED GAS, N.O.S. (1,1,1,3,3-Pentafluoropropane) 2.2 2.2 200 200 |
| | UN 3163 LIQUEFIED GAS, N.O.S. (1,1,1,3,3-PENTAFLUOROPROPANE) 2.2 |
| Pag | e 12 / 15 |

Honeywell

Genetron® 245fa

| 0322628 ersion 2.13 | Revision Date 09/22/2023 | Print Date 09/20/202 | | |
|---|---|----------------------|--|--|
| Hazard Labels EmS Number Marine pollutant | : 2.2 : F-C, S-V : no | | | |
| SECTION 15. REGULATORY INFORMATION | | | | |
| Inventories | | | | |
| US. Toxic Substances Control Act | : On TSCA Inventory | | | |
| Australia. Inventory of Industrial Chemicals (AIIC), as amended | : On the inventory, or in compliance with the | e inventory | | |
| Canada. Canadian Environmental Protection Act (CEPA). Domestic Substances List (DSL) | : All components of this product are on the 0 | Canadian DSL | | |
| Japan. Kashin-Hou Law List | : On the inventory, or in compliance with the | e inventory | | |
| Korea. Existing Chemicals Inventory (KECI) | : On the inventory, or in compliance with the | e inventory | | |
| Philippines. Inventory of Chemicals and Chemical Substances (PICCS) | : Not in compliance with the inventory | | | |
| China. Inventory of Existing Chemical Substances (IECSC) | : On the inventory, or in compliance with the | e inventory | | |
| New Zealand. Inventory of Chemicals (NZIoC), as published by ERMA New Zealand | : On the inventory, or in compliance with the | e inventory | | |
| Taiwan Chemical Substance Inventory (TCSI) | : On the inventory, or in compliance with the | e inventory | | |
| National regulatory informa | tion | | | |
| | Page 13 / 15 | | | |

Honeywell

Genetron® 245fa

10322628

| 0322628 | | | |
|---------------------------------|---|-----------------------------------|--|
| ersion 2.13 | Revision Date 09/22/2023 | Print Date 09/20/2024 | |
| | | | |
| SARA 302 Components | : No chemicals in this material are sub | viect to the reporting | |
| SARA 302 Components | requirements of SARA Title III, Section | | |
| | | 511002. | |
| SARA 313 Components | : This material does not contain any cl | | |
| | known CAS numbers that exceed the | | |
| | reporting levels established by SARA | A The III, Section 313. | |
| SARA 311/312 Hazards | : Sudden Release of Pressure Hazard | | |
| | Acute Health Hazard | | |
| | • | | |
| California Prop. 65 | · · ^ | | |
| | WARNING: This product can e | | |
| | listed below, known to the State of California to cause cancer. | | |
| | For more information go to www.P65 | ovvarnings.ca.gov. | |
| | Dichloromethane | 75-09-2 | |
| | | | |
| Massachusetts RTK | : Dichloromethane | 75-09-2 | |
| | | | |
| | | 75 00 0 | |
| Pennsylvania RTK | : Dichloromethane | 75-09-2 | |
| | | | |
| ECTION 16. OTHER INFORM | IATION | | |
| | HMIS III NFPA | | |
| Health hazard | : 2 2 · 1 1 | | |
| Flammability Physical Hazard | : 1 1 : 0 | | |
| Instability | : 0 | | |
| | | | |
| Hazard rating and rating s | ystems (e.g. HMIS® III, NFPA): This informa | tion is intended solely for the u | |
| of individuals trained in the | | | |

Further information

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and

Page 14 / 15

Honeywell

Genetron® 245fa

10322628

Version 2.13

Revision Date 09/22/2023

Print Date 09/20/2024

may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. Final determination of suitability of any material is the sole responsibility of the user. This information should not constitute a guarantee for any specific product properties.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.

Previous Issue Date: 08/08/2018

Prepared by Honeywell Performance Materials and Technologies Product Stewardship Group

Page 15 / 15